Targeting the undruggable: immunotherapy meets personalized oncology in the genomic era.

Details

Ressource 1Download: serval:BIB_044E24F585FB.P001 (369.80 [Ko])
State: Public
Version: author
License: Not specified
It was possible to publish this article open access thanks to a Swiss National Licence with the publisher.
Serval ID
serval:BIB_044E24F585FB
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Targeting the undruggable: immunotherapy meets personalized oncology in the genomic era.
Journal
Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo
Author(s)
Martin S.D., Coukos G., Holt R.A., Nelson B.H.
ISSN
1569-8041 (Electronic)
ISSN-L
0923-7534
Publication state
Published
Issued date
2015
Peer-reviewed
Oui
Volume
26
Number
12
Pages
2367-2374
Language
english
Notes
Publication types: Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't ; Review
Publication Status: ppublish
Abstract
Owing to recent advances in genomic technologies, personalized oncology is poised to fundamentally alter cancer therapy. In this paradigm, the mutational and transcriptional profiles of tumors are assessed, and personalized treatments are designed based on the specific molecular abnormalities relevant to each patient's cancer. To date, such approaches have yielded impressive clinical responses in some patients. However, a major limitation of this strategy has also been revealed: the vast majority of tumor mutations are not targetable by current pharmacological approaches. Immunotherapy offers a promising alternative to exploit tumor mutations as targets for clinical intervention. Mutated proteins can give rise to novel antigens (called neoantigens) that are recognized with high specificity by patient T cells. Indeed, neoantigen-specific T cells have been shown to underlie clinical responses to many standard treatments and immunotherapeutic interventions. Moreover, studies in mouse models targeting neoantigens, and early results from clinical trials, have established proof of concept for personalized immunotherapies targeting next-generation sequencing identified neoantigens. Here, we review basic immunological principles related to T-cell recognition of neoantigens, and we examine recent studies that use genomic data to design personalized immunotherapies. We discuss the opportunities and challenges that lie ahead on the road to improving patient outcomes by incorporating immunotherapy into the paradigm of personalized oncology.
Keywords
Animals, Cancer Vaccines/administration & dosage, Genomics/methods, Genomics/trends, Humans, Immunotherapy/methods, Immunotherapy/trends, Neoplasms/immunology, Neoplasms/therapy, Precision Medicine/methods, Precision Medicine/trends, T-Lymphocytes/immunology
Pubmed
Web of science
Open Access
Yes
Create date
11/01/2016 18:31
Last modification date
25/09/2019 7:08
Usage data